|
Published by: SMI Publishing, Ltd
Published: Oct. 20, 2011
Table of Contents- DAY 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.).
- 9.10 Aetiology & pathogenesis of exacerbations of COPD
- Role of bacteria and viruses in COPD exacerbations
- Human and mouse models of COPD exacerbations
- Mechanisms of COPD exacerbations
- Identification of novel approaches to therapy
- Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.).
- 9.50 Reducing the burden of COPD by targeting skeletal muscle mass and function
- Evidence to support the importance of skeletal muscle dysfunction in COPD
- The benefits of physical training
- The potential for the skeletal muscles to be a target for drug development in COPD.
- Michael Steiner, Consultant Respiratory Physician, University Hospital Leicester.
- 10.30 Morning Coffee
- 11.00 COPD, a developing disease: clinical perspective and lessons from Asthma
- Pathogenesis
- COPD as a developing disease
- Development of COPD specific therapies
- Inherent difficulties with the disease
- A bright future?
- Ewan Walters, Medical Director, Teva UK Ltd.
- 11.40 Panel Discussion: Novel Therapeutics and unmet needs in COPD
- Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.).
- 12.40 Networking Lunch
- 1.50 Clinical testing and uses of ‘roflumilast’
- Deciding who should use roflumilast
- Correct dosages
- How long should it be used for
- What evidence of improvements to look for in patients using it
- When to stop administering roflumilast
- Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust.
- 2.30 Combination therapy for COPD
- New ICS/LABA combinations: What and why
- Switching on Inhaled Corticosteroids: Novel anti-inflammatory combinations
- Combination bronchodilators: Optimising symptomatic benefit
- Mary Fitzgerald, Executive VP, Respiratory, Pulmagen Therapeutics.
- 3.10 Afternoon Tea
- 3.40 Inhaled models of Inflammation in Phase I/II clinical trials
- Integrated Phase I study designs
- Addressing mechanism of action
- Allergen, LPS and Ozone challenges
- Surrogate biomarkers – Nasal challenge
- Graham Clarke, Head of Respiratory Phase I, Quintlies Ltd..
- 4.20 Anti-inflammatory therapies
- Targeting inflammation in COPD: options and limitations
- Approved and emerging anti-inflammatory drugs for the treatment of COPD
- Translating anti-inflammatory potency into clinical benefit
- Daniel Bock, Director Preclinical and Clinical R&D, Revotar Biopharmaceuticals.
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.).
- DAY 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Maria Belvisi, Head of Respiratory Pharmocology Group, Imperial College.
- 9.10 Diagnosing and Phenotyping COPD Patients
- COPD is a heterogeneous condition and although definition is based around the measurement of airflow limitation, the FEV1 does not describe the heterogeneity of the condition
- A number of proposed phenotypes of COPD have been suggested which may relevance for outcomes in COPD and targeted treatment
- COPD phenotypes and their clinical relevance will be described
- Future options for treatment targeted towards COPD phenotypes will be discussed
- Bill MacNee, Professor of Medicine, University Of Edinburgh Medical School.
- 9.50 Targeting the immunological basis of COPD
- The immunology of COPD
- Autoimmunity and COPD
- Targeting the immunopathology of COPD
- Matthew Catley, Head of Disease Area Pharmacology, UCB.
- 10.30 Morning Coffee
- 11.00 Rodent models of COPD exacerbations
- What are exacerbations and why target them?
- What aspects of exacerbations can be modelled in rodent models?
- How can we translate the findings back to man?
- Liz Hardaker, Investigator II, Novartis.
- 11.40 Pre-clinical models of COPD
- Human and rodent tissue and cell based assays
- Pharmacodynamic models
- In vivo models of steroid resistant inflammation
- Functional endpoints
- Maria Belvisi, Head of Respiratory Pharmocology Group, Imperial College.
- 12.20 Networking Lunch
- 1.40 The Management of COPD exacerbations
- Issues regarding acute exacerbations
- Pharmacological & non-pharmacological management
- Outcomes of exacerbations
- Integration of services
- Organisation of care
- Wisia Wedzicha, Professor of Respiratory Medicine, University College London.
- 2.20 Modelling clinical outcomes of COPD
- Developing an ensemble outcome(clinical endpoints) model to enable therapeutic development in COPD
- Statistical challenges
- Progress so far
- 3.00 Panel Discussion: COPD clinical trials from start to finish
- Maria Belvisi, Head of Respiratory Pharmocology Group, Imperial College.
- Graham Clarke, Head of Respiratory Phase I, Quintlies Ltd..
- Wisia Wedzicha, Professor of Respiratory Medicine, University College London.
- 4.00 Afternoon Tea and Close of Day Two
AbstractSMi proudly present their 3rd annual COPD: Novel Therapeutics and Management Strategies conference to be held in Central London on Wednesday 19th and Thursday 20th of October 2011. Bringing together high level industry representatives as well as highly respected academic and medical figures, this is your opportunity to enjoy presentations on the latest hot topics surrounding COPD and to network with key industry professionals.
This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.
The conference agenda covers every phase of COPD study. We begin with a clinical perspective taking into account new targets for COPD and lessons that can be learned in future development and desgin. The most controversial of these novel therapeutics, roflumilast, is explored from a pharmacological and clinical perspective. This is followed with looks at combination and inhaled therapeutics.
The agenda focuses on discovery and devlopment from various interesting viewpoints, with pre and post clinical modelling and strategy addressed as well as Phase I & II studies.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
